Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: Therapeutic implications

Clinical Cancer Research

Volumn 7, Issue 1, 2001, Pages 158-167

  Dimitroulakos, Jim ^a   Ye, Lily Y ^a,c   Benzaquen, Mark ^a,c   Moore, Malcolm J ^a,c   Kamel Reid, Suzanne ^a,d   Freedman, Melvin H ^b   Yeger, Herman ^b,d   Penn, Linda Z ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTONE; MEVALONIC ACID; MEVINOLIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL VIABILITY; CHILDHOOD CANCER; CYTOTOXICITY; ENZYME INHIBITION; HEAD CANCER; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; NECK CANCER; NEUROBLASTOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLOW CYTOMETRY; FORMAZANS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MASS SPECTROMETRY; MEVALONIC ACID; MICROSCOPY, ELECTRON; NEOPLASMS; TETRAZOLIUM SALTS; TUMOR CELLS, CULTURED;

EID: 0035132669     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Induction of apoptosis in fibroblasts by c-myc protein
2. Apoptosis: Its clinical significance in cancer and cancer therapy
3. Social controls on cell survival and cell death
4. Cell death in development
5. Apoptosis. Biochemical events and relevance to cancer chemotherapy
6. Apoptosis in cancer therapy: Crossing the threshold
7. Therapeutic strategies involving the multidrug resistance phenotype: The MDR1 gene as target, chemoprotectant, and selectable marker in gene therapy
8. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture
9. Biochemistry of multidrug resistance mediated by the multidrug transporter
10. Ras C-terminal processing enzymes - New drug targets?
11. Inhibitors of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
12. Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho
13. Retinoids and their receptors in differentiation, embryogenesis and neoplasia
14. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study
15. Cellular origin of cancer: Dedifferentiation or stem cell maturation arrest?
16. Cancer chemoprevention
17. Retinoids in head and neck chemoprevention
18. Differentiation therapy with all-trans retinoic acid in acute myeloid leukemia
19. Suppression of squamous cell carcinoma growth and differentiation by retinoids
20. Retinoids as modulators of tumor cells invasion and metastasis
21. Retinoic acid and retinoic acid receptors in development
22. Identification of a novel zinc finger gene, zf5-3, as a potential mediator of neuroblastoma differentiation
23. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein-expressing cells
24. Regulation of the mevalonate pathway
25. Pharmacology of competitive inhibitors of HMG-CoA reductase
26. HMG-CoA reductase inhibitors
27. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase
28. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin
29. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
30. Lovastatin induces apoptosis in malignant mesothelioma cells
31. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro
32. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells
33. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach
34. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias
35. Autocrine and paracrine growth control by granulocyte-monocyte colony-stimulating factor of acute lymphoblastic leukemia cells
36. Identification of human juvenile chronic myelogenous leukemia stem cells capable of initiating the disease in primary and secondary SCID mice
37. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
38. Tetrazolium-based assays for cellular viability: A critical examination of selected parameters affecting formazan production
39. The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets
40. Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: Predicting biochemical mechanism of action
41. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer
42. Retinoids: Present role and future potential
43. Features of apoptotic cells measured by flow cytometry
44. Multiple cell cycle access to the apoptotic death programme in human neuroblastoma cells
45. Lovastatin 5-year safety and efficacy study
46. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin, and prevastatin on leukaemic and normal bone marrow progenitors
47. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia